03:51 PM EST - Lorus Therapeutics Inc. : announced that its Phase I clinical study of LOR-253 has successfully escalated to the target dose level based on predicted and observed clinical effects without limitation by toxicity. The success of this study allows Lorus to initiate a biomarker clinical investigation to further explore the effects of the drug at relevant doses determined in the clinical trial. Lorus Therapeutics Inc.
shares T.LOR are trading up $0.03 at $0.40.
